Android app on Google Play

Map Pharma (MAPP) Hosting Call to Discuss Levadex: Doesn't Expect to Change Device Amid CRL, to Submit Request for FDA Meeting Today

March 27, 2012 8:36 AM EDT Send to a Friend
Get Alerts MAPP Hot Sheet
Price: $24.98 --0%

Financial Fact:
Interest expense: 0

Today's EPS Names:
NTZ, More
Trade MAPP Now!
Join SI Premium – FREE
Map Pharma (Nasdaq: MAPP) is currently hosting an investor call related to Levadex. Below are some highlights.
  • The FDA did not request more clinical studies and instead is concerned with third-party manufacturing.
  • The FDA also had questions about the usability of the inhaler.
  • The Administration asked for more time to review data.
  • MAP's CEO Tim Nelson said he doesn't expect any need for a change to the device.
  • The company will submit a request for an FDA meeting today.
  • An FDA meeting with the company may be 60-75 days away.
  • Issues with the FDA have no effect on the company's contract with Allergan (NYSE: AGN).
Shares of MAP Pharma last traded at $14 even, down more than 18 percent from Monday's close.

You May Also Be Interested In

Related Categories

Conference Calls, Corporate News, FDA

Add Your Comment